Using the Translational Science Benefits Model to assess the impact of the Penn Implementation Science Center in Cancer Control.

Traditional approaches for evaluating the impact of scientific research - mainly scholarship (i.e., publications, presentations) and grant funding - fail to capture the full extent of contributions that come from larger scientific initiatives. The Translational Science Benefits Model (TSBM) was developed to support more comprehensive evaluations of scientific endeavors, especially research designed to translate scientific discoveries into innovations in clinical or public health practice and policy-level changes. Here, we present the domains of the TSBM, including how it was expanded by researchers within the Implementation Science Centers in Cancer Control (ISC3) program supported by the National Cancer Institute. Next, we describe five studies supported by the Penn ISC3, each focused on testing implementation strategies informed by behavioral economics to reduce key practice gaps in the context of cancer care and identify how each study yields broader impacts consistent with TSBM domains. These indicators include Capacity Building, Methods Development (within the Implementation Field) and Rapid Cycle Approaches , implementing Software Technologies , and improving Health Care Delivery and Health Care Accessibility . The examples highlighted here can help guide other similar scientific initiatives to conceive and measure broader scientific impact to fully articulate the translation and effects of their work at the population level.
Competing Interests: Justin E. Bekelman reports grants from AstraZeneca, Emerson Collective, Loxo@Lilly, and Gilead and personal fees from Reimagine Care, Healthcare Foundry, and AstraZeneca, outside the submitted work. David A. Asch is a partner at VAL Health and has received grants from UnitedHealth Group and personal fees from Deloitte, MARS Veterinary Group, and Boehringer Ingelheim. Krisda H. Chaiyachati reports employment and equity ownership in Verily Life Sciences; honoraria from the Robert Wood Johnson Foundation; and is on the board of directors for the American Board of Internal Medicine and Intend Health Strategies. Susan M. Domchek reports consulting fees from AstraZeneca and GlaxoSmithKline. Oluwadamilola M. Fayanju reports grants paid to her institution from Gilead, Inc. outside the submitted work. Katherine L. Nathanson reports serving on a Scientific Advisory Board for Merck, unrelated to the current study. Katharine A. Rendle reports receiving grants from Pfizer and AstraZeneca paid to her institution, personal fees from Merck for serving as a scientific consultant, and honoraria and travel paid as an invited speaker from MJH Life Sciences outside the submitted work. Rinad S. Beidas is the principal at Implementation Science & Practice, LLC. She has received royalties from Oxford University Press, consulting fees from United Behavioral Health and OptumLabs, and serves on the advisory boards for AIM Youth Mental Health Foundation and the Klingenstein Third Generation Foundation. She also currently serves on the National Advisory Mental Health Council and NASEM Blueprint for a National Prevention Infrastructure for Behavioral Health Disorders study outside of the submitted work.
(© The Author(s) 2024.)